IBD: Crohn's Disease

What’s Health Canada Saying about Biosimilars?

A biosimilar biologic drug, or biosimilar, is a drug demonstrated to be highly similar to a biologic drug that was already authorized for sale (known as the reference biologic drug). Biosimilars are approved based on a thorough comparison to a reference drug and may enter the market after the expiry of reference drug patents and data protection. Watch this video to get more insight into what Health Canada is saying about biosimilars!

This video was made possible by an unrestricted educational grant by Pfizer Canada.

IBD Treatment Options: Understanding Your Benefits and Risks (Ulcerative Colitis)

IBD Treatment Options: Understanding Your Benefits and Risks (Crohn’s Disease)

Making informed decisions is imperative to your good health but understanding the benefits and risks associated with Crohn’s Disease treatment options can be challenging. CDHF developed […]

Blackboards and Bathrooms – A comprehensive resource to help teachers support the education of children with IBD

Blackboards and Bathrooms was developed by the Canadian Digestive Health Foundation in collaboration with Robbies Rainbow. Blackboards and Bathrooms has been created especially for you – the […]

What is ulcerative colitis?

Ulcerative colitis is a chronic disorder affecting the large intestine (colon). The digestive system (including the stomach, small and large intestines) converts food into nutrients and […]

What’s Health Canada Saying about Biosimilars?

https://www.youtube.com/embed/6DkzQFdyNuY

IBD: Crohn's Disease

What’s Health Canada Saying about Biosimilars?

Related Articles

What’s Health Canada Saying about Biosimilars?